Bcs Wealth Management Bristol Myers Squibb CO Transaction History

Bcs Wealth Management

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 10, 2024	BUY	$47.98 - $54.4 $73,793 - $83,667	1,538 Added 35.98%	5,813 $315,000
Q4 2023 Jan 11, 2024	BUY	$48.48 - $57.85 $145 - $173	3 Added 0.07%	4,275 $219,000
Q3 2023 Oct 12, 2023	BUY	$57.89 - $64.73 $247,306 - $276,526	4,272 New	4,272 $248,000
Q4 2022 Jan 10, 2023	SELL	$68.48 - $81.09 $37,047 - $43,869	-541 Reduced 10.56%	4,582 $330,000
Q3 2022 Oct 07, 2022	SELL	$0.13 - $76.84 $43 - $25,818	-336 Reduced 6.15%	5,123 $364,000
Q2 2022 Jul 29, 2022	SELL	$72.62 - $79.98 $29,411 - $32,391	-405 Reduced 6.91%	5,459 $420,000
Q1 2022 Apr 28, 2022	SELL	$61.48 - $73.72 $76,972 - $92,297	-1,252 Reduced 17.59%	5,864 $428,000
Q4 2021 Jan 18, 2022	BUY	$53.63 - $62.52 $18,234 - $21,256	340 Added 5.02%	7,116 $444,000
Q3 2021 Oct 25, 2021	SELL	$59.17 - $69.31 $18,224 - $21,347	-308 Reduced 4.35%	6,776 $401,000
Q2 2021 Jul 21, 2021	SELL	$61.91 - $67.42 $4,643 - $5,056	-75 Reduced 1.05%	7,084 $473,000
Q1 2021 Apr 28, 2021	BUY	$59.34 - $66.74 $118 - $133	2 Added 0.03%	7,159 $452,000
Q4 2020 Jan 21, 2021	BUY	$57.74 - $65.43 $115 - $130	2 Added 0.03%	7,157 $444,000
Q3 2020 Oct 23, 2020	SELL	$57.43 - $63.64 $228,858 - $253,605	-3,985 Reduced 35.77%	7,155 $431,000
Q2 2020 Jul 21, 2020	BUY	$54.82 - $64.09 $50,215 - $58,706	916 Added 8.96%	11,140 $655,000
Q1 2020 Apr 10, 2020	BUY	$46.4 - $67.43 $301,507 - $438,160	6,498 Added 174.4%	10,224 $570,000
Q4 2019 Feb 10, 2020	BUY	$49.21 - $64.19 $183,356 - $239,171	3,726 New	3,726 $239,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Bcs Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Bcs Wealth Management with notifications on news.